Short interest for SNDL gives investors a sense of the degree to which investors are betting on the decline of SNDL's stock. Short interest data is updated every two weeks.

SNDL Stock (NASDAQ:SNDL), Short Interest Report

SNDL

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

elsa-olofsson-12-Zs1xIEtA-unsplash(20)

Cannabis

Earnings

News

NOVC

TSX:NOVC

SNDL Inc. reported on Thursday its financial and operational results for the first quarter ended March 31, 2024.The company reported a total net revenue of CA$197.7 million, up from CA$191 million in the prior year&#39;s period. Out of that sum cannabis retail revenue amounted to CA$71.3 million, while cannabis operations totaled CA$22.4 million.SNDL attributed the increase to the cannabis retail and cannabis operations segments, as the liquor retail segment reported flat net revenue.

SNDL Cannabis Co. Wraps Up Q1 With No Outstanding Debt As It Works On Expanding In US

Wall Street

Intraday Update

Markets

Movers

AESI

BCRX

BOWL

CRML

EYPT

IART

MARA

OCGN

PACB

PRFT

SAVE

SLQT

TRUP

UNIT

Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday&#39;s Mid-Day Session

cannabis contract signing BZCCC (Iryna Rahalskaya on Shutterstock)(40)

SNDL Inc. through its joint venture with SunStream Bancorp Inc., announced on Thursday that SunStream USA group of companies will proceed with the process of acquisition of equity positions in U.S. cannabis assets, following the completion of a review by SNDL&#39;s listing authority, NASDAQ. SunStream USA I, LLC and SunStream USA II, LLC are among the entities that comprise the SunStream USA Group, with each entity including one or more third-party investors, all independently managed and governed.The Calgary, Alberta-based company said on Thursday that SNDL&#39;s affiliate, SunStream Opportunities II LP, is anticipated to own non-voting and non-participating exchangeable securities in the SunStream USA entities.  

Canadian Giant SNDL Speeds Up Acquisition Of Majority Positions In Two US Cannabis Companies As Marijuana Rescheduling Looms

SNDL Inc

<p>The GOP-controlled House Armed Services Subcommittee on Military Personnel is advancing significant changes to military recruitment policies, while also exploring therapeutic avenues <a href="https://www.benzinga.com/topic/military">for active-duty personnel.</a></p>
<p><strong>What happened</strong>: The House Armed Services Subcommittee on Military Personnel unveiled recommendations this week within the 2025 National Defense Authorization Act (NDAA) that address both cannabis and psychedelics regulations, <a href="https://www.marijuanamoment.net/house-committee-proposes-ending-marijuana-testing-for-military-recruits-in-defense-bill/">reported</a> Marijuana Moment. These provisions are slated for consideration in the upcoming full committee markup, underscoring their significance.</p>
<p>One key aspect of the proposal involves an end to marijuana testing for enlistment or commissioning purposes. This recommendation, an initiative previously spearheaded by <strong>Rep. Matt Gaetz</strong> (R-FL), underscores the collaborative efforts within the GOP. At the time, <a href="https://www.benzinga.com/markets/cannabis/23/07/33127611/rep-matt-gaetz-wants-to-end-cannabis-testing-for-us-military-citing-recruitment-crisis">Gaetz said eliminating</a> cannabis testing could help the military meet its&nbsp;recruitment goals.</p>
<p>Last summer, records <a href="https://www.nytimes.com/2023/04/30/us/marijuana-drugs-federal-jobs.html">obtained </a>by&nbsp;The New York Times revealed that the federal government was struggling to replace its aging workforce and recruiters were responding by loosening drug screening rules.</p>
<p>The Department of Defense's (DOD) acknowledgment of delta-9 THC as a prevalent substance in military drug tests underscores the rationale behind the proposed testing ban. Additionally, certain military branches have already begun relaxing cannabis-related restrictions, signaling a broader shift in policy.</p>
<p>In early 2024, the U.S. Navy began <a href="https://www.benzinga.com/markets/cannabis/24/02/37068701/us-navy-overlooks-recruits-past-cannabis-use-to-reduce-boot-camp-dropouts-and-recruitment-challe">implementing significant changes</a> in its boot camp policy, opting to grant waivers to recruits who test positive for cannabis. This shift was a departure from the Navy's previous zero-tolerance approach, reflecting the evolving legal landscape of cannabis while addressing its own recruiting challenges.</p>
<h2 class="wp-block-heading">Defense Department&#8217;s Clinical Trials On Therapeutic Psychedelics</h2>
<p>Along with the cannabis provisions, the subcommittee advocated for robust oversight of <a href="https://www.benzinga.com/markets/cannabis/23/12/36160210/bicameral-broad-defense-bill-mandates-psychedelics-clinical-trials-for-active-service-members">DOD-led clinical trials</a> on the therapeutic potential of psychedelics. This includes a call for progress updates to ensure the effective establishment of these programs with US House Rep. <strong>Morgan Luttrell</strong> (R-TX), a former Navy SEAL who is championing the cause.</p>
<p>Bipartisan support for psychedelics medicine <a href="https://www.benzinga.com/markets/cannabis/24/05/38816048/video-psychedelics-surpass-cannabis-with-unprecedented-bipartisan-support-in-congress-says-top-v">has surged</a>, in fact surpassing that of marijuana, as evidenced by recent discussions within the Department of Veterans Affairs (VA). </p>
<p><em>Now read: <a href="https://www.benzinga.com/markets/cannabis/24/05/38816048/video-psychedelics-surpass-cannabis-with-unprecedented-bipartisan-support-in-congress-says-top-v">Psychedelics Surpass Cannabis With Unprecedented Bipartisan Support In Congress, Says Top VA Official</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Government

GOP-Led Committee Pushes To Ban Cannabis Tests For Military Recruits, Inquires On Psychedelics Trials

<p><strong>Eli Lilly And Co</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has reportedly reached a settlement agreement with a&nbsp;medi&nbsp;spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38596771/weigh-loss-competition-heats-up-in-britain-online-pharmacies-slash-prices-for-wegovy-and-mounjaro" rel="noreferrer noopener">which contains tirzepatide</a>.</p>
<p>As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly&#8217;s branding to promote its products.</p>
<p>In addition to the financial settlement, Totality Medispa&nbsp;is required&nbsp;to&nbsp;take corrective actions, including ensuring that any compounded tirzepatide products it obtains and&nbsp;distributes&nbsp;are&nbsp;produced&nbsp;in compliance with U.S. federal law.</p>
<p><strong><em>Related</em></strong><em>:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38563149/eli-lilly-on-its-way-to-1-trillion-market-cap-analysts-say-its-a-have-in-a-sea-of-h" rel="noreferrer noopener">Eli Lilly &#8216;On Its Way&#8217; To $1 Trillion Market Cap, Analysts Say: It&#8217;s A &#8216;Have&#8217; In A Sea Of &#8216;Have Nots&#8217;</a></em></p>
<p>In April, U.S. District Judge Roy Altman&nbsp;<a target="_blank" href="https://cases.justia.com/federal/district-courts/florida/flsdce/1:2023cv23586/654456/46/0.pdf?ts=1712851105" rel="noreferrer noopener">ruled</a>&nbsp;that&nbsp;<strong>Eli Lilly</strong>&nbsp;cannot rely on state law to stop a compounding pharmacy,&nbsp;<strong>RXCompoundStore.com</strong>, from marketing its version&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38223582/eli-lilly-suffers-legal-loss-for-its-popular-weight-lossdiabetes-drug-in-lawsuit-against-florida-" rel="noreferrer noopener">of the drug tirzepatide</a>.</p>
<p>Eli Lilly and&nbsp;<strong>Novo Nordisk A/S&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) have actively pursued legal action against several&nbsp;medi&nbsp;spas&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36765784/weight-loss-drugs-ozempic-counterfeit-rising-reports-over-patient-safety-related-fake-drugs" rel="noreferrer noopener">and compounding pharmacies</a>.&nbsp;</p>
<p>These lawsuits aim to halt the sale of products that falsely claim to contain the active ingredients semaglutide and tirzepatide, which&nbsp;are used&nbsp;in the companies&#8217; popular weight-loss drugs.&nbsp;</p>
<p>Last year, Novo Nordisk sued a compounding pharmacy and refiled a lawsuit against another after discovering that their products, which purported to contain the active ingredient for its weight-loss drug Wegovy, were impure&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/36020513/novo-nordisk-sues-florida-compounding-pharmacies-over-impurities-in-products-claiming-to-contain-" rel="noreferrer noopener">by as much as 33%</a>.</p>
<p>In March, Lilly reported finding bacteria and high levels of impurities in products alleged to be compounded&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37544347/eli-lillys-legal-battle-against-fake-compounded-tirzepatide-products-bacteria-impurities-detected" rel="noreferrer noopener">versions of tirzepatide</a>.&nbsp;</p>
<p>The company has since taken legal action against multiple medical spas, weight-loss clinics, and compounding pharmacies to prevent them from selling products purportedly containing tripeptide, the active ingredient in its&nbsp;weight-loss&nbsp;and diabetes medications.</p>
<p>&#8220;While this agreement is an important step forward, this is not a problem that Lilly can solve alone. We strongly support state and federal regulators taking action to deter and punish compounding pharmacies, counterfeiters, and others who put patients at risk by selling unsafe products claiming to be tirzepatide,&#8221; Reuters noted, citing Lilly&#8217;s statement.</p>
<p><em>Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37662893/pharmaceutical-crime-jumps-50-as-criminals-seek-to-capitalize-rising-tide-of-counterfeit-weight-l" rel="noreferrer noopener">Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs</a>.</em></p>
<p><strong>Price Action</strong>:&nbsp;LLY shares were&nbsp;up 1.21% at $773.22&nbsp;at&nbsp;last&nbsp;check Wednesday.</p>
<p><em>Photo via Company</em></p>


Biotech

Large Cap

Health Care

Legal

General

Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound

<p>B. Riley Securities  analyst Christopher Souther   maintains Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) with a Buy and lowers the price target from $7 to $6.</p>


Price Target

Analyst Ratings

AMPS

B. Riley Securities Maintains Buy on Altus Power, Lowers Price Target to $6

AAPL

Apple Plans Accessibility Features Including Eye Tracking, Music Haptics And Vocal Shortcuts

<p>Raytech Holding Limited (the "Company" or "RAY"), a Hong Kong-headquartered company specializes in design, sourcing and wholesale of personal care electrical appliances for international brand owners, today announced the pricing of its initial public offering (the "Offering") of 1,500,000 ordinary shares (the "Ordinary Shares") at a public offering price of $4 per share for total gross proceeds of $6,000,000, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and commenced trading today, under the ticker symbol "RAY".<br /><br />&nbsp;</p>
<p>The Company has granted the underwriters an option, exercisable within 45 days from the closing date of the Offering, to purchase up to an additional 225,000 Ordinary Shares at the initial public offering price, less underwriting discounts, to cover over-allotments, if any.</p>


IPOs

Raytech Holding Prices $6M IPO Of 1.5M Ordinary Shares At A Price Of $4/Share

<p>UBS  analyst Alex Kramm   maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Buy and raises the price target from $120 to $130.</p>


UBS Maintains Buy on Tradeweb Markets, Raises Price Target to $130

<p>High-rolling investors have positioned themselves bearish on Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SHOP often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Shopify. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 33% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $36,120, and 8 calls, totaling $357,417.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $115.0 for Shopify over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Shopify stands at 1963.75, with a total volume reaching 1,560.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Shopify, situated within the strike price corridor from $50.0 to $115.0, throughout the last 30 days.</p>
<h3>Shopify Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781731_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$90.00</td>
<td>$133.6K</td>
<td>1.0K</td>
<td style="text-align: right;">316</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$115.00</td>
<td>$42.8K</td>
<td>1.2K</td>
<td style="text-align: right;">112</td>
</tr>
<tr>
<td>SHOP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.65</td>
<td>$8.5</td>
<td>$8.6</td>
<td>$60.00</td>
<td>$36.1K</td>
<td>7.6K</td>
<td style="text-align: right;">68</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$3.5</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$60.00</td>
<td>$34.5K</td>
<td>3.2K</td>
<td style="text-align: right;">280</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$60.00</td>
<td>$31.0K</td>
<td>3.2K</td>
<td style="text-align: right;">506</td>
</tr>
</tbody>
</table>
</p>
<h3>About Shopify</h3>
<p>Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.</p>
<p>In light of the recent options history for Shopify, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Shopify</h3>
<ul>
<li>Currently trading with a volume of 2,008,098, the SHOP's price is up by 0.56%, now at $58.35. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shopify options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

SHOP

Smart Money Is Betting Big In SHOP Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>ARM Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ARM, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for <strong>ARM Holdings</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 16%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $53,250, and 11, calls, for a total amount of $619,913.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $230.0 for ARM Holdings over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ARM Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ARM Holdings's substantial trades, within a strike price spectrum from $90.0 to $230.0 over the preceding 30 days.</p>
<h3>ARM Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781726_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$2.69</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$125.00</td>
<td>$104.0K</td>
<td style="text-align: right;">598</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$33.3</td>
<td>$32.95</td>
<td>$33.3</td>
<td>$90.00</td>
<td>$103.2K</td>
<td style="text-align: right;">129</td>
<td style="text-align: right;">31</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$42.4</td>
<td>$41.75</td>
<td>$42.4</td>
<td>$95.00</td>
<td>$71.9K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$22.95</td>
<td>$19.55</td>
<td>$21.91</td>
<td>$230.00</td>
<td>$67.3K</td>
<td style="text-align: right;">25</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$28.75</td>
<td>$28.35</td>
<td>$28.75</td>
<td>$100.00</td>
<td>$63.1K</td>
<td style="text-align: right;">612</td>
<td style="text-align: right;">73</td>
</tr>
</tbody>
</table>
</p>
<h3>About ARM Holdings</h3>
<p>Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Both off-the-shelf and architectural customers pay a royalty fee per chip shipped.</p>
<p>In light of the recent options history for ARM Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is ARM Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,668,920, the ARM's price is down by -1.11%, now at $115.36. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 92 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ARM Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At ARM Holdings's Recent Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Reddit. Our analysis of options history for Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 61% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $62,900, and 11 were calls, valued at $863,225.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $75.0 for Reddit during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Reddit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Reddit's significant trades, within a strike price range of $40.0 to $75.0, over the past month.</p>
<h3>Reddit Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781721_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$15.0</td>
<td>$13.9</td>
<td>$15.0</td>
<td>$45.00</td>
<td>$300.0K</td>
<td style="text-align: right;">515</td>
<td style="text-align: right;">404</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$45.00</td>
<td>$165.0K</td>
<td style="text-align: right;">515</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$45.00</td>
<td>$112.0K</td>
<td style="text-align: right;">515</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$17.45</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$45.00</td>
<td>$49.5K</td>
<td style="text-align: right;">515</td>
<td style="text-align: right;">133</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$10.65</td>
<td>$8.0</td>
<td>$9.34</td>
<td>$55.00</td>
<td>$46.7K</td>
<td style="text-align: right;">556</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Reddit</h3>
<p>Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.</p>
<p>Following our analysis of the options activities associated with Reddit, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Reddit Standing Right Now?</h3>
<ul>
<li>With a volume of 947,990, the price of RDDT is down -6.92% at $58.02. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 102 days.</li>
</ul>
<h3>What The Experts Say On Reddit</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $54.4.</p>
<ul>
<li>Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Reddit, targeting a price of $63. </li>
<li>Consistent in their evaluation, an analyst from Bernstein keeps a Underperform rating on Reddit with a target price of $45. </li>
<li>Consistent in their evaluation, an analyst from Goldman Sachs keeps a Neutral rating on Reddit with a target price of $55. </li>
<li>An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $46. </li>
<li>An analyst from JMP Securities has decided to maintain their Market Outperform rating on Reddit, which currently sits at a price target of $63. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Reddit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RDDT

Market Whales and Their Recent Bets on RDDT Options

<p>Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Tronox Holdings, presenting an average target of $21.75, a high estimate of $24.00, and a low estimate of $19.00. Witnessing a positive shift, the current average has risen by 22.54% from the previous average price target of $17.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781681_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Tronox Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tronox Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tronox Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Tronox Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tronox Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TROX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tronox Holdings analyst ratings.</strong></a></p>
<h2>Discovering Tronox Holdings: A Closer Look</h2>
<p>Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia &amp; South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. North America, Asia-Pacific and Europe the Middle East, and Africa regions contribute the vast majority of revenue.</p>
<h3>Tronox Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Tronox Holdings displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.32%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Tronox Holdings's net margin excels beyond industry benchmarks, reaching <strong>-1.16%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Tronox Holdings's ROE excels beyond industry benchmarks, reaching <strong>-0.47%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Tronox Holdings's ROA excels beyond industry benchmarks, reaching <strong>-0.15%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Tronox Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.56</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TROX

Analyst Scoreboard: 4 Ratings For Tronox Holdings

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for PENN Entertainment, presenting an average target of $25.19, a high estimate of $33.00, and a low estimate of $17.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.63%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781671_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive PENN Entertainment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Shaun Kelley</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.50</td>
<td>$28.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ryan Sigdahl</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Felicia Hendrix</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$23.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$23.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PENN Entertainment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PENN Entertainment compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of PENN Entertainment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into PENN Entertainment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PENN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on PENN Entertainment analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind PENN Entertainment</h2>
<p>Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 89% of total sales in 2023; 11% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.</p>
<h3>Key Indicators: PENN Entertainment's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, PENN Entertainment faced challenges, resulting in a decline of approximately <strong>-3.97%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> PENN Entertainment's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-7.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> PENN Entertainment's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.66%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> PENN Entertainment's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.73%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>3.72</strong>, PENN Entertainment adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PENN

Beyond The Numbers: 18 Analysts Discuss PENN Entertainment Stock

Trading Ideas

AWIN

AERWINS Technologies Shares Resume Trade

LIDR

AEye Shares Resume Trade

<p>In the last three months, 14 analysts have published ratings on Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $149.43, a high estimate of $182.00, and a low estimate of $105.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.52%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781650_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Global Payments. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$152.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$164.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$157.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$129.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Global Payments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Global Payments compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Global Payments's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Global Payments's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GPN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Global Payments analyst ratings.</strong></a></p>
<h2>About Global Payments</h2>
<p>Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.</p>
<h3>Global Payments: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Global Payments's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>5.57%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Global Payments's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.95%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Global Payments's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.39%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.61%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.82</strong>, Global Payments adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 14 Analyst Insights On Global Payments

GameStop Corp. Shares Resume Trade

<p>During the last three months, 6 analysts shared their evaluations of Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.67, a high estimate of $160.00, and a low estimate of $140.00. This current average has increased by 12.53% from the previous average price target of $135.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781640_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Crane. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$157.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ronald Epstein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Crane. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crane compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Crane's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Crane's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Crane analyst ratings.</strong></a></p>
<h2>All You Need to Know About Crane</h2>
<p>Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into three segments: aerospace and electronics, process flow technologies, and engineered materials. Crane generated approximately $2.1 billion in revenue in 2023.</p>
<h3>Crane's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Crane's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.02%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Crane's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>11.46%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Crane's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>4.69%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Crane's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.73%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.26</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Crane Through Analyst Insights

<p>Ratings for Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $26.42, a high estimate of $37.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.92%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781628_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Privia Health Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Craig Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Adam Ron</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Privia Health Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Privia Health Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Privia Health Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Privia Health Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRVA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Privia Health Gr analyst ratings.</strong></a></p>
<h2>Delving into Privia Health Gr's Background</h2>
<p>Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.</p>
<h3>Unraveling the Financial Story of Privia Health Gr</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Privia Health Gr showcased positive performance, achieving a revenue growth rate of <strong>7.5%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Privia Health Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.72%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Privia Health Gr's ROE excels beyond industry benchmarks, reaching <strong>0.52%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Privia Health Gr's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.29%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PRVA

What 12 Analyst Ratings Have To Say About Privia Health Gr

<p>Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) has outperformed the market over the past 15 years by 7.11% on an annualized basis producing an average annual return of 19.67%. Currently, Jabil has a market capitalization of $13.96 billion. </p>
<p><strong>Buying $1000 In JBL:</strong> If an investor had bought $1000 of JBL stock 15 years ago, it would be worth <strong>$14,149.76</strong> today based on a price of $115.75 for JBL at the time of writing.</p>
<h3>Jabil's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781623_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Jabil 15 Years Ago Would Be Worth This Much Today

<p><strong>AMC</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) stock is back in the news as Roaring Kitty returned to social media, igniting rallies in the stocks that led the last "meme stock mania," including AMC and <strong>GameStop</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>).&nbsp;</p>
<p>However, many investors are staying on the sidelines because they can&#8217;t stomach the volatility. If you are one of these investors and want another way to play AMC stock in particular, you could invest in one of its largest landlords.</p>
<h2 class="wp-block-heading"><strong>EPR Properties</strong></h2>
<p><strong>EPR Properties</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) is a leading owner and manager of experiential real estate. Its portfolio currently consists of <a href="https://eprkc.com/who-we-are/about-epr/">359</a> entertainment, recreation, education, and leisure properties, including movie theaters, golf ranges, waterparks, amusement parks, fitness centers, private schools, and early childhood education centers. Movie theaters make up 37% of its portfolio with tenants including AMC, Cinemark, Regal, and Alamo Drafthouse.</p>
<h2 class="wp-block-heading"><strong>In the Spotlight:</strong></h2>
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Here's how you can collect passive rental income without being a landlord</a>.</li>
<li>Elon Musk, Ken Griffin and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/cityfunds-yield">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
<p>EPR Properties currently pays a monthly dividend of $0.285 per share, equating to an annualized dividend of $3.42 per share, which gives its stock a yield of about _% at the time of this writing..</p>
<p>EPR had an impressive track record of dividend growth before it was forced to suspend its dividend as a result of the Covid-19 pandemic. However, with operations back to normal, the company is on pace for 2024 to mark the third consecutive year in which it has raised its annual dividend payment, and this could be the start to a very long streak.</p>
<p>EPR is a great way to play the success of AMC over the long term.</p>
<h2 class="wp-block-heading"><strong>More to Read:</strong></h2>
<ul>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to this <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Jeff Bezos-backed startup to generate monthly rental income without having to purchase their own property</a>.</li>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000.</a></li>
</ul>
<p><em>Image Credit: Shutterstock</em></p>


REIT

Real Estate

This Is a Much Safer Way to Invest in the Success of AMC Stock

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 5 years by 14.86% on an annualized basis producing an average annual return of 27.78%. Currently, Apollo Global Management has a market capitalization of $63.74 billion. </p>
<p><strong>Buying $100 In APO:</strong> If an investor had bought $100 of APO stock 5 years ago, it would be worth <strong>$348.65</strong> today based on a price of $112.02 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715781617_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

Lifeway Foods and SNDL among Consumer Staples movers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology.&nbsp;</p>



<p>The first company is a shining light in biotechnology due to its innovative cell therapy platform. It shows great potential for treating autoimmune disorders such as refractory lupus nephritis. Similarly, the second one takes advantage of the energy sector&rsquo;s volatility by maximizing cash flow. It does this through solid financial methods and high operating leverage. Meanwhile, the third company dominates the cannabis business with solid sales growth and increased profitability.</p>



<p>In the long term, there is certainly high potency. The first one promises to cure many autoimmune ailments, the second one has a record-breaking performance based on solid market rates, and the third has a sharp increase in sales and gross profit margins in the cannabis sector. These companies offer profitable prospects for investors eager to enter new areas and exhibit durability in the face of market changes. These are the next major movers that Wall Street is&nbsp;keeping an eye on.</p>



<h2>Nkarta (NKTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/nktx_cancerresearch1600-300x169.png" alt="DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT Stock"><div>Source: CI Photos / Shutterstock.com</div></div><p>The refractory lupus nephritis (LN) patients treated by <strong>Nkarta&rsquo;s</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nktx-stock-quote/"><strong>NKTX</strong></a></span>) NKX019 reflect&nbsp;<a href="https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">progressive outcomes</a>. This clinical achievement highlights the therapeutic potential of the company&rsquo;s patented cell therapy technology. </p>



<p>Additionally, the company focuses on massive demand in autoimmune illnesses, with the planned initiation of a clinical trial in refractory LN patients. Moreover, the assessment of NKX019&rsquo;s efficacy against B cells derived from patients suffering from&nbsp;autoimmune disorders underscores its relevance in various medical conditions. Certainly, NKX019 is a&nbsp;progressive option for additional research in autoimmune illnesses (other than LN).</p>



<p>Further, there are positive clinical results from&nbsp;<a target="_blank" href="https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2023-financial">Nkarta&rsquo;s Phase 1 study</a>&nbsp;of NKX019 in patients with r/r non-Hodgkin lymphoma (NHL).&nbsp;This&nbsp;highlights the long-term efficacy and durability of its cell treatment strategy for hematologic malignancies. The therapeutic promise of NKX019 in NHL is validated by the excellent complete response rate in patients receiving NKX019 monotherapy.&nbsp;</p>



<p>Finally, the positive re-treatment results prove NKX019&rsquo;s therapeutic efficacy and promise for long-term disease control. These are observed in patients who relapsed after receiving&nbsp;<a href="https://ir.nkartatx.com/static-files/4c521906-fdb6-4525-ac1c-c5a456f9b0be" target="_blank">their first therapy</a>.&nbsp;Overall, these results uphold NKX019&rsquo;s ongoing development in NHL and solidify Nkarta&rsquo;s leadership in cell therapy.</p>



<h2>Teekay Tankers (TNK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/oil-tanker-1600-300x169.png" alt="Aerial front side view of oil tanker ship sailing on open sea, Imperial Petroleum (IMPP) operates oil tankers"><div>Source: Igor Karasi / Shutterstock.com</div></div><p>High operating leverage helps <strong>Teekay Tankers</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/tnk-stock-quote/"><strong>TNK</strong></a></span>) with high spot rates for its tankers. The company generates around&nbsp;<a href="https://www.teekay.com/wp-content/uploads/2024/03/TNK-Q4-23-Earnings-Results-Transcript.pdf" target="_blank">$2.5 of yearly free cash flow&nbsp;</a>(<a href="https://investorplace.com/stock-quotes/fcf-stock-quote/"><strong>FCF</strong></a>) per share for every $5K rise in tanker rates beyond its FCF breakeven point of $16K&nbsp;per day.&nbsp;This leverage enhances the company&rsquo;s growth potential, enabling it to take advantage of favorable market circumstances and create substantial cash flow.</p>



<p>Moreover, with an adjusted net income of&nbsp;<a href="https://www.teekay.com/wp-content/uploads/2024/02/TNK-Q4-23-ER-Document.pdf" target="_blank">$500.5 million</a>, or $14.65 per share, Teekay Tankers broke all previous records in 2023&nbsp;and more than doubled its impressive 2022 results. This solid boost demonstrates the company&rsquo;s fundamental capacity to capitalize on advantageous market conditions and derive a bottom line.</p>



<p>Further,&nbsp;initiatives are being taken to enhance the company&rsquo;s financial standing and lessen its debt load. For instance, Teekay Tankers plans to repurchase eight boats for <a href="https://www.teekay.com/wp-content/uploads/2024/02/TNK-Q4-23-ER-Document.pdf" target="_blank">$137 million</a> under sale-leaseback terms.&nbsp;This brings the total number of vessels repurchased since March 2023 to 27, with a total value of $501 million.&nbsp;Overall, these efforts aim to boost flexibility and resilience by reducing cash breakeven rates and achieving zero total debt outstanding.</p>



<h2>SNDL (SNDL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/sndl-1600-300x169.png" alt="The Sundial Growers logo is on a phone screen with a light blue background in front of the sundial logo on a white background. SNDL stock"><div>Source: Shutterstock</div></div><p>The performance of <strong>SNDL</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sndl-stock-quote/"><strong>SNDL</strong></a></span>) in 2023 reflects solid gross profit margins and top-line growth, which provides a solid basis for the company&rsquo;s potential for rapid expansion. The company&rsquo;s net sales increased considerably by&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_news/SNDL-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-and-Operational-Results-2024.pdf" target="_blank">28% year-over-year</a>&nbsp;(YoY) from the prior year to&nbsp;$909 million. This&nbsp;indicates that SNDL may boost its market share and profit from the spiking demand for booze and cannabis goods.</p>



<p>To dive further, SNDL&rsquo;s top-line growth trajectory is especially vital when focusing on Q1 2023 performance. The year started with a spectacular&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_earnings/2023/q4/transcript/final-sndl-inc-q4-2023-results.pdf" target="_blank">over 1,000% YoY</a>&nbsp;revenue boost in Q1, which showcased SNDL&rsquo;s capacity to seize market opportunities and generate significant top-line growth.</p>



<p>In addition, SNDL&rsquo;s gross profit margins increased to a record high in 2023, reaching <a href="https://s201.q4cdn.com/372870431/files/doc_news/SNDL-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-and-Operational-Results-2024.pdf" target="_blank">$190 million,</a>&nbsp;or 21% of sales.&nbsp;In 2022, they were $140 million, or 20% of sales. Thus, SNDL&rsquo;s improved operational edge and cost-control techniques resulted in increased profitability. Overall, through a strategic focus on top-line growth and cost structure optimization, SNDL has effectively fortified its financial standing and set itself up for swift progress.</p>



<p><em>On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/opportunity-alert-3-undiscovered-stocks-about-to-explode-on-wall-streets-radar/">Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street&#8217;s Radar</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar

SNDL reports Q1 results

Sndl Inc. (SNDL) has released an update. SNDL Inc. reports modest changes in its financial position for the first quarter of 2024, with total asset...

SNDL Inc. Q1 Financials Indicate Stability

Beyond Meat and SNDL among Consumer Staples movers

Sndl Inc. (SNDL) has released an update. SNDL Inc. has announced a positive shift in its financial landscape, with a 4% year-over-year increase in ...

SNDL Inc. Reports Growth and Record Margins

Sndl Inc. (SNDL) has released an update. SNDL Inc. and Nova Cannabis Inc. have successfully completed the transfer of ownership of four Dutch Love ...

SNDL Divests Dutch Love Stores to Nova Cannabis

SNDL Inc. (SNDL) Q1 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Cannabis may be one of the most controversial investing topics. But, it&rsquo;s also turning out to be one of the most profitable. Look at <strong>Canopy Growth</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgc-stock-quote/"><strong>CGC</strong></a>), for example. Since bottoming out at around $2.77 in March, it hit a high of $14.92.&nbsp;&nbsp;Now at $9.86, it could race even higher. All thanks to substantial catalysts that could send undervalued <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> to higher highs.</p>



<p>For one, according to a recent Pew Research poll, 88% of Americans want to see legalization. Two, more U.S. states could legalize it. Three, the Drug Enforcement Agency just said it would reschedule cannabis as a less severe drug. </p>



<p>Four, as we near the presidential election in November, we could hear more about the potential for federal legalization given its popularity among 88% of Americans.&nbsp;In addition, Germany just legalized its use, which could set off a domino effect of legalization throughout Europe.</p>



<p>We could go on, but you get the point. Cannabis stocks are hot and could see higher highs. Here are seven undervalued cannabis stocks you may want to consider buying today, with some paying dividends.</p>



<h2><strong>Innovative Industrial Properties (<strong>IIPR</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-7-300x169.jpg" alt="A close-up shot of a marijuana growhouse. cannabis trends"><div>Source: Shutterstock</div></div><p>The last time I mentioned<strong> Innovative Industrial Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/iipr-stock-quote/"><strong>IIPR</strong></a>), it traded at <a href="https://investorplace.com/2024/04/want-more-green-buy-these-3-red-hot-cannabis-stocks-today/">around $97 on April 23</a>. After hitting a high of $111.71, it&rsquo;s pulling back on healthy profit-taking and a revenue miss and is still a strong buy opportunity.&nbsp;</p>



<p>For one, with a yield of 6.95%, the real estate investment trust (<span>REIT</span>) focused on the acquisition, and management of state-licensed cannabis operators, just paid out a dividend of $1.82.&nbsp;</p>



<p>Two, earnings were mixed, but should improve moving forward. <a href="https://seekingalpha.com/news/4103082-innovative-industrial-properties-ffo-of-2_21-beats-0_16-revenue-of-75_5m-misses-3_01m">First quarter adjusted funds from operations (AFFO)</a>, for example, came in at $2.21, which beat by 16 cents. Unfortunately, revenue of $75.5 million, down 0.8% year-over-year (YOY) did miss by $3.01 million. In addition, with cannabis sales set to improve, and interest rates likely to fall, bullish trends could push IIPR higher.</p>



<p>At the moment, the REIT own 108 properties across 19 states with 8.9 million rentable square feet. Also, 95.2% of its portfolio is under a triple-net lease.</p>



<h2><strong>AFC Gamma (<strong>AFCG</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/cannabis-stocks1600-300x169.png" alt="Marijuana Cannabis Leaf Stock Market Symbol Company Business 3d Illustration. Cannabis stocks"><div>Source: iQoncept / Shutterstock.com</div></div><p>The last time I mentioned <strong>AFC Gamma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/afcg-stock-quote/"><strong>AFCG</strong></a>), it traded at <a href="https://investorplace.com/2024/04/dank-dividends-3-cannabis-reits-offering-high-yields/">$11.50 on April 15</a>. It would hit a high of $12.66. And while I still like the cannabis REIT &ndash; especially for its 15.5% yield &ndash; I&rsquo;d wait for it to pull back first. It&rsquo;s starting to slip from double-top resistance and could potentially slip back to $11.75 near term.&nbsp;</p>



<p>Earnings were mixed here, too. While EPS of 49 cents beat by six cents, net interest income of $14.76 million &ndash; down 12.3% YOY &ndash; missed by $1.33 million. However, much like IIPR, with cannabis sales likely to increase and hopeful interest rate cuts on the way, AFCG could push higher, as well.&nbsp;</p>



<p>At the moment, &ldquo;AFC Gamma targets direct lending and bridge loan opportunities typically ranging from $5 million to $100 million across multiple real estate sectors, with a specialization in loans to state-licensed cannabis operators,&rdquo; <a href="https://investors.afcgamma.com/news-releases/news-release-details/afc-gamma-separate-commercial-real-estate-lending-business">as noted on its site</a>.</p>



<h2>NewLake Capital Partners (NLCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/marijuana-cannabis-stocks-1600-300x169.png" alt="marijuana stocks Hand gently holding rich soil for his marijuana plants. Cannabis Stocks"><div>Source: Jetacom Autofocus / Shutterstock.com</div></div><p>There&rsquo;s also <strong>NewLake Capital Partners</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/nlcp-stock-quote/"><strong>NLCP</strong></a>), which I also <a href="https://investorplace.com/2024/04/dank-dividends-3-cannabis-reits-offering-high-yields/">mentioned on April 15</a> as another one of the top undervalued cannabis stocks</p>



<p>At the time, it traded at about $18. Today, it&rsquo;s up to $20.55 and is also overbought. While I do like the stock for its 8% yield, I&rsquo;d also wait for it to pull back before buying. It&rsquo;s another REIT that should benefit from improving sales, and eventual rate cuts from the Federal Reserve.</p>



<p>The REIT, which provides real estate capital to licensed cannabis operators through sale-leaseback transactions and owns a portfolio of 31 properties comprised of 14 cultivation facilities and 17 dispensaries, did post impressive earnings.</p>



<p>In its first quarter, funds from operations came in at 50 cents, which beat by four cents. Revenue of $12.6 million &ndash; up 10.5% YOY &ndash; beat by $620,000.</p>



<p>Also, <a href="https://www.globenewswire.com/news-release/2024/05/09/2878761/0/en/NewLake-Capital-Partners-Reports-First-Quarter-2024-Financial-Results.html">Anthony Coniglio, President and CEO, said</a>: </p>




<p>&ldquo;Our growth in revenue and AFFO year-over-year and sequentially, after deducting one-time adjustments in the fourth quarter, are what drove our second consecutive quarterly dividend increase to $0.41 per share, or $1.64 per share annually.&rdquo;</p>




<p>He added:</p>




<p>&ldquo;Looking forward, the cannabis industry has much to be excited about following the proposal to reschedule cannabis from Schedule I to Schedule 3, an increase in meaningful dialogue among congressional leaders, and medical to adult-use conversion in&nbsp;Ohio&nbsp;and the Adult-use ballot in Florida.&rdquo;</p>




<h2><strong>ETFMG Alternative Harvest ETF (<strong>MJ</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-2-300x169.png" alt="Business marijuana leaves cannabis stocks success market price green arrow up profit growth charts graph money display screen up industry trend grow higher quickly / Commercial cannabis medicine money"><div>Source: Bigc Studio / Shutterstock.com</div></div><p>Or, if you want to safely diversify with top undervalued cannabis stocks at a low price of $4.18, look at the <strong>ETFMG Alternative Harvest ETF</strong>&nbsp;(NYSEARCA:<a href="https://investorplace.com/stock-quotes/mj-stock-quote/"><strong>MJ</strong></a>).&nbsp;</p>



<p>With an&nbsp;<a href="https://etfmg.com/funds/mj/">expense ratio</a>&nbsp;of 0.75%, the ETF tracks the performance of cannabis companies benefiting from global medicinal and recreational use. While its chart isn&rsquo;t too attractive at the moment, give it time. With news of rescheduling, state legalization, and the potential for federal legalization, the MJ ETF and its holdings could see higher highs, with patience.</p>



<p>Some of its top holdings include&nbsp;<strong>Tilray</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tlry-stock-quote/"><strong>TLRY</strong></a>), Innovative Industrial,&nbsp;<strong>SNDL Inc.</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sndl-stock-quote/"><strong>SNDL</strong></a>),&nbsp;<strong>Cronos Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cron-stock-quote/"><strong>CRON</strong></a>), Canopy Growth, and&nbsp;AFC Gamma Inc.&nbsp;to name a few of the top ones.</p>



<p>After bottoming out at around $2.60 a share, the MJ ETF is now up to $4.18. From here, if it can break above resistance at $4.83 a share, I&rsquo;d like to see it retest $6 moving forward.</p>



<h2><strong>Advisor Shares Pure US Cannabis ETF (<strong>MSOS</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-6-300x169.jpg" alt="cannabis stocks, With America Turning Green Things Only Can Get Better for Aurora Stock"><div>Source: Shutterstock</div></div><p>After bottoming out at around $5.13 in November, the <strong>Advisor Shares Pure US Cannabis ETF</strong> (NYSEARCA:<a href="https://investorplace.com/stock-quotes/msos-stock-quote/"><strong>MSOS</strong></a>) ran to a high of $11.37. Now at $9.35, it&rsquo;s still a strong buy that could double as the cannabis story heats up.</p>



<p>With an expense ratio of 0.60%, the MSOS ETF&nbsp;is the first actively managed U.S.-listed ETF with dedicated cannabis exposure focusing exclusively on U.S. companies, including multi-state operators, as noted on the ETF&rsquo;s site. Some of its top holdings include <strong>Green Thumb Industries</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/gtbif-stock-quote/"><strong>GTBIF</strong></a>), <strong>Curaleaf Holdings</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/"><strong>CURLF</strong></a>), <strong>Trulieve Cannabis</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcnnf-stock-quote/"><strong>TCNNF</strong></a>), and <strong>Cresco Labs</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/crlbf-stock-quote/"><strong>CRLBF</strong></a>).</p>



<p>As I usually note, ETFs are a great investment. Not only do they allow you to diversify with dozens of stocks, but they&rsquo;re also cheaper. You can buy MSOS ETF, for example, for less than $10, while gaining exposure to its 25 holdings.</p>



<h2><strong>Curaleaf Holdings (<strong>CURLF</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/cannabis-stocks1600-1-300x169.png" alt="Business cannabis leaves marijuana stock exchange market or trading analysis investment indicator graph charts. The concept of a company or stock market of marijuana exports for medical use. Cannabis stocks"><div>Source: C.Aphirak / Shutterstock.com</div></div><p>There are also undervalued cannabis stocks like Curaleaf. After bottoming out at around $2.50, it raced to a high of $6.40. Now back to $5.50, the undervalued cannabis stock could also race higher.&nbsp;</p>



<p>For one,&nbsp;the&nbsp;<a href="https://www.morningstar.com/news/marketwatch/20240223360/cannabis-stocks-rise-as-germany-takes-first-big-step-toward-broader-legalization-in-europe">recent legalization in Germany</a>&nbsp;could have a domino effect across Europe, where CURLF has been expanding its footprint. For example, CURLF recently acquired <strong>Northern Green Canada</strong>, which is one of a few Canadian cultivators with EU-GMP (European Union &ndash; Good Manufacturing Process) certification.</p>



<p>In addition, <a href="http://%E2%80%9CIt%20has%20consistently%20supplied%20high-THC,%20non-irradiated%20flower%20to%20the%20German%20market,%20which%20is%20expected%20to%20see%20exponential%20growth%20following%20the%20recent%20removal%20of%20cannabis%20from%20the%20narcotics%20list.%20NGC%20is%20also%20increasingly%20supplying%C2%A0Australia%C2%A0and%C2%A0New%20Zealand,%20the%20world%E2%80%99s%20fastest-growing%20cannabis%20markets.%E2%80%9D">according to the Green Market Report</a>: </p>




<p>&ldquo;It has consistently supplied high-THC, non-irradiated flower to the German market, which is expected to see exponential growth following the recent removal of cannabis from the narcotics list. NGC is also increasingly supplying Australia and&nbsp;New Zealand, the world&rsquo;s fastest-growing cannabis markets.&rdquo;</p>




<p>Two, CURLF is considering a secondary listing in Europe to help &ldquo;<a href="https://seekingalpha.com/news/4087654-curaleaf-reportedly-eyeing-stock-listing-in-europe">bolster shareholder value</a>,&rdquo; as noted by Seeking Alpha.</p>



<h2><strong>Green Thumb Industries (<strong>GTBIF</strong>)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/gtbif1600-300x169.png" alt=""><div>Source: Wirestock Creators / Shutterstock.com</div></div><p>We can also look at Green Thumb Industries, an undervalued&nbsp;cannabis consumer packaged goods company and owner of&nbsp;RISE Dispensaries trading at just $12.81.</p>



<p>Since bottoming out at around $6.42 in August, GTBIF raced to a high of $16.33. Now back to $12.81, it&rsquo;s still a strong buy. In its most recent quarter, the company&rsquo;s first quarter revenue of $276 million was up 11% YOY.&nbsp;</p>



<p>&ldquo;Gross profit for the first quarter 2024 was $144.9 million or 52.5% of revenue compared to $124.7 million or 50.2% of revenue for the first quarter 2023,&rdquo; <a href="https://www.morningstar.com/news/globe-newswire/9113826/green-thumb-industries-reports-first-quarter-2024-results#:~:text=Gross%20profit%20for%20the%20first,revenue%20growth%20in%20the%20quarter.">they added</a>. &ldquo;Net income attributable to the Company for the first quarter 2024 was $31.1 million or $0.13 per basic and diluted share, an increase from net income of $9.1 million, or $0.04 per basic and diluted share in the prior year period.&rdquo;</p>



<p>Analysts at Needham also raised their price target on GTBIF to $17, with a buy rating. All after the company&rsquo;s impressive first quarter earnings, which beat expectations.&nbsp;</p>



<p><em>On the date of publication, Ian Cooper&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/the-7-most-undervalued-cannabis-stocks-to-buy-in-may-2024/">The 7 Most Undervalued Cannabis Stocks to Buy in May 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 7 Most Undervalued Cannabis Stocks to Buy in May 2024

AFCG

BRCC

BTTR

BYND

CLEU

COOT

CRLBF

CRON

CURLF

DTCK

EAST

FRPT

GROV

GSUN

GTBIF

IIPR

KAVL

LINC

LWAY

MSOS

NKTX

NLCP

SHOT

SMFL

STKL

TCNNF

TLRY

VITL

Press Releases

SNDL to Announce First Quarter 2024 Financial Results on May 9, 2024

Cannabis Stocks On The Move Amid DEA Reclassification Indication

SunStream USA Poised to Acquire Cannabis Assets

Contracts

SNDL and Nova Cannabis Complete the Assignment of Dutch Love Stores to Nova Cannabis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SNDL Stock (NASDAQ:SNDL), Short Interest Report

People Also Watch